Safety and efficacy of percutaneous image-guided ablation for soft tissue sarcoma metastases to the liver.
ablation technique
hepatic
interventional radiology
metastases
soft tissue sarcoma
survival
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
20 Apr 2024
20 Apr 2024
Historique:
revised:
07
03
2024
received:
26
01
2024
accepted:
19
03
2024
medline:
20
4
2024
pubmed:
20
4
2024
entrez:
20
4
2024
Statut:
aheadofprint
Résumé
To evaluate outcomes following percutaneous image-guided ablation of soft tissue sarcoma metastases to the liver. A single-institution retrospective analysis of patients with a diagnosis of metastatic soft tissue sarcoma who underwent percutaneous image-guided ablation of hepatic metastases between January 2011 and December 2021 was performed. Patients with less than 60 days of follow-up after ablation were excluded. The primary outcome was local tumor progression-free survival (LPFS). Secondary outcomes included overall survival, liver-specific progression-free survival. and chemotherapy-free survival. Fifty-five patients who underwent percutaneous ablation for 84 metastatic liver lesions were included. The most common histopathological subtypes were leiomyosarcoma (23/55), followed by gastrointestinal stromal tumor (22/55). The median treated liver lesions was 2 (range, 1-8), whereas the median size of metastases were 1.8 cm (0.3-8.7 cm). Complete response at 2 months was achieved in 90.5% of the treated lesions. LPFS was 83% at 1 year and 80% at 2 years. Liver-specific progression-free survival was 66% at 1 year and 40% at 2 years. The overall survival at 1 and 2 years was 98% and 94%. The chemotherapy-free holiday from the start of ablation was 71.2% at 12 months. The complication rate was 3.6% (2/55); one of the complications was Common Terminology Criteria for Adverse Events grade 3 or higher. LPFS subgroup analysis for leiomyosarcoma versus gastrointestinal stromal tumor suggests histology-agnostic outcomes (2 years, 89% vs 82%, p = .35). Percutaneous image-guided liver ablation of soft tissue sarcoma metastases is safe and efficacious.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 American Cancer Society.
Références
von Mehren M, Kane JM, Bui MM, et al. NCCN guidelines insights: soft tissue sarcoma, version 1.2021. J Natl Compr Cancer Netw JNCCN. 2020;18(12):1604‐1612. doi:10.6004/jnccn.2020.0058
Farid M, Ngeow J. Sarcomas associated with genetic cancer predisposition syndromes: a review. Oncology. 2016;21(8):1002‐1013. doi:10.1634/theoncologist.2016‐0079
Katz D, Palmerini E, Pollack SM. More than 50 subtypes of soft tissue sarcoma: paving the path for histology‐driven treatments. Am Soc Clin Oncol Educ Book. 2018;38:925‐938. doi:10.1200/edbk_205423
Falk AT, Moureau‐Zabotto L, Ouali M, et al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. Clin Oncol R Coll Radiol G B. 2015;27(1):48‐55. doi:10.1016/j.clon.2014.09.010
Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer Oxf Engl. 1990. 2013;49(3):684‐695. doi:10.1016/j.ejca.2012.09.011
Blay JY, Coindre JM, Ducimetière F, Ray‐Coquard I. The value of research collaborations and consortia in rare cancers. Lancet Oncol. 2016;17(2):e62‐e69. doi:10.1016/s1470‐2045(15)00388‐5
Carmagnani PR, Moyers JT, Roszik J, et al. Impact of biomarker‐matched therapies on outcomes in patients with sarcoma enrolled in early‐phase clinical trials (SAMBA 101). Clin Cancer Res. 2023;29(9):1708‐1718. doi:10.1158/1078‐0432.ccr‐22‐3629
ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(suppl 3):iii102‐112.
de Baere T, Tselikas L, Gravel G, et al. Interventional radiology: role in the treatment of sarcomas. Eur J Cancer Oxf Engl. 1990. 2018;94:148‐155. doi:10.1016/j.ejca.2018.02.017
Sutton C, Zhang Y, Kim D, et al. Analysis of the chemotherapy‐free interval following image‐guided ablation in sarcoma patients. Sarcoma. 2020;2020:e3852420‐e3852428. doi:10.1155/2020/3852420
Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single‐center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg Chic Ill 1960. 2006;141(6):537‐543. Discussion 543‐544. doi:10.1001/archsurg.141.6.537
Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 2000;88(1):66‐74. doi:10.1002/(sici)1097‐0142(20000101)88:1<66::aid‐cncr10>3.0.co;2‐0
Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992;69(6):1334‐1341. doi:10.1002/1097‐0142(19920315)69:6<1334::aid‐cncr2820690606>3.0.co;2‐s
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51‐58. doi:10.1097/00000658‐200001000‐00008
Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft‐tissue sarcoma. Ann Surg. 1995;221(4):392‐397. doi:10.1097/00000658‐199504000‐00010
Ahmed M, Solbiati L, Brace CL, et al. Image‐guided tumor ablation: standardization of terminology and reporting criteria—a 10‐year update. J Vasc Interv Radiol JVIR. 2014;25(11):1691‐1705.e4. doi:10.1016/j.jvir.2014.08.027
17. Common Terminology Criteria for Adverse Events (CTCAE). 2017.
Brudvik KW, Patel SH, Roland CL, et al. Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2015;19(8):1476‐1483. doi:10.1007/s11605‐015‐2845‐9
Goumard C, Marcal LP, Wang WL, et al. Long‐term survival according to histology and radiologic response to preoperative chemotherapy in 126 patients undergoing resection of non‐GIST sarcoma liver metastases. Ann Surg Oncol. 2018;25(1):107‐116. doi:10.1245/s10434‐017‐6144‐4
Romero AM, Schillemans W, Os Rvan, et al. The Dutch–Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: clinical outcomes of 515 patients and 668 metastases. Int J Radiat Oncol Biol Phys. 2021;109(5):1377‐1386. doi:10.1016/j.ijrobp.2020.11.045
Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi‐institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572‐1578. doi:10.1200/jco.2008.19.6329
Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol. 2001;8(4):290‐299. doi:10.1245/aso.2001.8.4.290
Groeschl RT, Pilgrim CHC, Hanna EM, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195‐1200. doi:10.1097/sla.0000000000000234
Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi‐institutional RSSearch® Patient Registry. Radiat Oncol. 2018;13(1):26. doi:10.1186/s13014‐018‐0969‐2
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472‐480. doi:10.1056/nejmoa020461
Verweij J, Casali PG, Zalcberg J, et al. Progression‐free survival in gastrointestinal stromal tumours with high‐dose imatinib: randomised trial. Lancet Lond Engl. 2004;364(9440):1127‐1134. doi:10.1016/s0140‐6736(04)17098‐0
Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(11):4182‐4190. doi:10.1158/1078‐0432.ccr‐04‐2245
Blanke CD, Demetri GD, von Mehren M, et al. Long‐term results from a randomized phase II trial of standard‐ versus higher‐dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620‐625. doi:10.1200/jco.2007.13.4403
Kim JH, Ryu MH, Yoo C, et al. Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: a 14‐year, single‐center experience. Cancer Med. 2019;8(3):1034‐1043. doi:10.1002/cam4.1994
DeMatteo RP, Ballman KV, Antonescu CR, et al. Placebo‐controlled randomized trial of adjuvant imatinib mesylate following the resection of localized, primary gastrointestinal stromal tumor (GIST). Lancet. 2009;373(9669):1097‐1104. doi:10.1016/s0140‐6736(09)60500‐6
Avritscher R, Gupta S. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematol Oncol Clin N Am. 2009;23(1):129‐137. doi:10.1016/j.hoc.2008.11.002
Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal. Tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer‐Italian Sarcoma Group‐Australasian Gastrointestinal Trials Group study.J Clin Oncol. 2005;23(24):5795‐5804, doi:10.1200/jco.2005.11.601
Jung JH, Won HJ, Shin YM, Kim PN. Safety and efficacy of radiofrequency ablation for hepatic metastases from gastrointestinal stromal tumor. J Vasc Intervent Radiol. 2015;26(12):1797‐1802. doi:10.1016/j.jvir.2015.09.002
Jones RL, McCall J, Adam A, et al. Radiofrequency ablation is a feasible therapeutic option in the multimodality management of sarcoma. Eur J Surg Oncol EJSO. 2010;36(5):477‐482. doi:10.1016/j.ejso.2009.12.005
Hakimé A, Hines‐Peralta A, Peddi H, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology. 2007;244(2):464‐470. doi:10.1148/radiol.2442061005